Resonance Health Limited Price Chart
Resonance Health Limited RHT.XA Financial and Trading Overview
| Resonance Health Limited stock price | 0.07 AUD |
| Previous Close | 0.04 AUD |
| Open | 0.04 AUD |
| Bid | 0.04 AUD x N/A |
| Ask | 0.04 AUD x N/A |
| Day's Range | 0.04 - 0.04 AUD |
| 52 Week Range | 0.04 - 0.08 AUD |
| Volume | 34.8K AUD |
| Avg. Volume | 39.07K AUD |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.973946 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.001 AUD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
RHT.XA Valuation Measures
| Enterprise Value | 10.85M AUD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.6521739 |
| Enterprise Value/Revenue | 2.666 |
| Enterprise Value/EBITDA | -6.715 |
Trading Information
Resonance Health Limited Stock Price History
| Beta (5Y Monthly) | 0.973946 |
| 52-Week Change | -36.66% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.08 AUD |
| 52 Week Low | 0.04 AUD |
| 50-Day Moving Average | 0.05 AUD |
| 200-Day Moving Average | 0.06 AUD |
RHT.XA Share Statistics
| Avg. Volume (3 month) | 39.07K AUD |
| Avg. Daily Volume (10-Days) | 28.04K AUD |
| Shares Outstanding | N/A |
| Float | 298.7M |
| Short Ratio | N/A |
| % Held by Insiders | 39.07% |
| % Held by Institutions | 7.79% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 30, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | -28.69% |
| Operating Margin (ttm) | -40.79% |
| Gross Margin | 100.00% |
| EBITDA Margin | -39.69% |
Management Effectiveness
| Return on Assets (ttm) | -8.52% |
| Return on Equity (ttm) | -10.60% |
Income Statement
| Revenue (ttm) | 4.07M AUD |
| Revenue Per Share (ttm) | 0.008 AUD |
| Quarterly Revenue Growth (yoy) | 11.50% |
| Gross Profit (ttm) | 3.85M AUD |
| EBITDA | -1615840 AUD |
| Net Income Avi to Common (ttm) | -1168161 AUD |
| Diluted EPS (ttm) | -0.001 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.53M AUD |
| Total Cash Per Share (mrq) | 0.01 AUD |
| Total Debt (mrq) | 318.57K AUD |
| Total Debt/Equity (mrq) | 3.06 AUD |
| Current Ratio (mrq) | 7.848 |
| Book Value Per Share (mrq) | 0.023 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -911225 AUD |
| Levered Free Cash Flow (ttm) | -1100360 AUD |
Profile of Resonance Health Limited
| Country | Australia |
| State | WA |
| City | Burswood |
| Address | 141 Burswood Road |
| ZIP | 6100 |
| Phone | 61 8 9286 5300 |
| Website | https://www.resonancehealth.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | N/A |
Resonance Health Limited, a healthcare technology and services company, designs, develops, and manufactures software-as-medical devices in the Asia Pacific, North America, South America, Europe, the Middle East, and Africa. It offers FerriScan, a non-invasive MRI based system for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) assisted device for the automated real-time assessment of LIC; HepaFat-AI, an AI-assisted device for the automated real-time multi-metric measurement of liver-fat; CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading; HepaFat-Scan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; and LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFat-AI into a consolidated report. It also offers quantitative imaging measurements and CRO, such as quality-assured image analysis, imaging charter development, project and data management, issue resolution, site tracker and clinical trial progress report, and coordination of data flow services; biomarkers, blood, urine, and protein analytes, as well as RNA, DNA, and genotyping services; and protocol development, assessment of subject inclusion or exclusion, decisions on dose modifications, and evaluating the safety profile of a new therapy, as well as supporting primary and secondary end-points demonstrating drug efficacy services for multinational and multicenter clinical trials; and phantoms for the calibration of MRI machines. The company serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for their clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.
Q&A For Resonance Health Limited Stock
What is a current RHT.XA stock price?
Resonance Health Limited RHT.XA stock price today per share is 0.07 AUD.
How to purchase Resonance Health Limited stock?
You can buy RHT.XA shares on the Cboe AU exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Resonance Health Limited?
The stock symbol or ticker of Resonance Health Limited is RHT.XA.
How many shares does Resonance Health Limited have in circulation?
The max supply of Resonance Health Limited shares is 0.
What is Resonance Health Limited Price to Earnings Ratio (PE Ratio)?
Resonance Health Limited PE Ratio is now.
What was Resonance Health Limited earnings per share over the trailing 12 months (TTM)?
Resonance Health Limited EPS is -0.001 AUD over the trailing 12 months.